success in quitting smoking appear to provide selective influence success in responding to bupropion, while others appear to provide selective influences on success in response to nicotine replacement. Replication and extension of these observations to treatments for alcohol, opiates and other addictive substances will make it more and more likely that SNP markers will increasingly aid “personalization” of antiaddiction therapies within the near future, in ways that are now impacting the design of clinical trials in this area.
